A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2016
At a glance
- Drugs Dasatinib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 29 Dec 2010 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 29 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.